|
Published by: Datamonitor
Published: Dec. 21, 2001 - 71 Pages
Table of Contents
DATAMONITOR HEALTHCARE
CONTACT DETAILS
EXECUTIVE SUMMARY
Datamonitor insight into the HIV Market
CHAPTER 1 INTRODUCTION
CHAPTER 2 ANALYSIS OF KEY Q4 DEVELOPMENTS
KEY HEADLINE - HIV-Associated Lipodystrophy Linked to Diet
COMPANY HEADLINES
HIV Resistance Testing Receives Increased Interest from the Pharmaceutical Industry
Gilead Gains US Approval for Viread
Roche Submits to Pressure on Expanded Access for T-20
RESEARCH AND DEVELOPMENT HEADLINES
BMS's Atazanavir Clinical Trial Data Released
TMC125 - Potentially the Most Potent Anti-HIV Drug to Date
Resistance to Viramune is Dependent on HIV-1 Subtype
p24 Antigen Test Offers Improvement Over RNA Testing
PIs Shown to Be Efficacious in Patients Failing 1st line HAART Therapy
NIH Awards Progenics Grant to Develop Entry Inhibitors
DISEASE SPECIFIC HEADLINES
Ten Years to Wait for AIDS Vaccine
HIV Intravenous Drug Users Unaware of Therapy Options
HIV is Highly Transmissible Directly After Primary Infection
Structured Treatment Intervals Beneficial in Treating HIV Patients
Drug Manufacturers Required to Include Lipodystrophy Information on Package Inserts
American Medical Association Backs Mandatory Prenatal HIV Testing
CDC Research Shows Key Populations Missed From US HIV Testing
EMERGING MARKETS HEADLINES
Roche Highlights Difficulties in Drug Delivery to Emerging Markets
GSK Offers Generics Manufacturer License for Three Anti-HIV Drugs
South African Government Accuses Pharmaceutical Industry
Singapore and China Joins the Race for Drug Discounts
CHAPTER 3 HIV-ASSOCIATED LIPODYSTROPHY
Introduction
Clinical definition of HIV-associated lipodystrophy
Causative factors of HIV-associated lipodystrophy
Epidemiology and prevalence of HIV-associated lipodystrophy
Diagnosis and treatment of HIV-associated lipodystrophy
Diagnosis of patients with HIV-associated lipodystrophy
Diagnostic Tools
Treatment of patients with HIV-associated lipodystrophy
Impact of HIV-associated lipodystrophy
Clinical Impact
Market Impact
Overview of non-HIV related lipodystrophy
Pharmaceutical company strategies
CHAPTER 4 AIDS WASTING
Disease Overview
History
Clinical definition of AIDS wasting
Causative factors of AIDS wasting
Epidemiology and prevalence of AIDS wasting
Diagnosis and treatment of AIDS wasting
Diagnosis of patients with AIDS wasting
Treatment of patients with AIDS wasting
Impact of AIDS wasting
Clinical Impact
Market Impact
Pharmaceutical company strategies
CHAPTER 5 CONCLUSIONS
CHAPTER 6 APPENDIX
Datamonitor's Infectious Disease Business Unit
Contributing experts
Bibliography
AbstractLipodystrophy is one of the principal co-morbidities associated with HIV infection, and, as the focus of therapy shifts towards quality of life issues, such co-morbidities will begin to impact upon the therapy market. This report analyses and differentiates lipodystrophy and AIDS Wasting, and discusses strategies pharmaceutical companies can use to counteract the commercial impact of these disorders. As with the our three previous 2001 HIV Updates, the report also covers in detail all the events that have impacted upon the HIV market in Q4 2001.
Get Full Details About This Report >>
|
